AstraZeneca is gearing up to present a wealth of new clinical, real-world, and early science data encompassing its Vaccines & Immune Therapies portfolio at the 34th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Barcelona, Spain from April 27th to April 30th, 2024. With 19 abstracts lined up for the event, including four oral presentations and four late-breaking presentations, the focus will be on underscoring the ongoing imperative to safeguard at-risk populations against the escalating burden of common infectious diseases, along with emphasizing the pivotal role of long-acting antibodies and vaccines.
Highlighted data to be showcased at the event will include:
- Real-world evidence showcasing the effectiveness of Beyfortus (nirsevimab), a long-acting antibody, in preventing hospitalizations due to respiratory syncytial virus (RSV).
- Updated real-world evidence shedding light on the persistent disproportionate burden of COVID-19 infection among immunocompromised individuals, underscoring the urgent need for enhanced protection.
- Pharmacokinetic and safety data on sipavibart, an investigational long-acting antibody aimed at preventing COVID-19 in immunocompromised individuals.
- Research updates on early pipeline assets, featuring a late-breaking oral presentation on a novel mRNA-VLP vaccine platform and data on a monoclonal antibody designed to prevent recurrent C. difficile infection.
Iskra Reic, Executive Vice President of Vaccines and Immune Therapies at AstraZeneca, expressed excitement about sharing data at ECCMID that showcases progress across both early- and late-stage Vaccines and Immune Therapies portfolios. Reic emphasized the company’s commitment to delivering enduring immunity against infectious diseases through innovative antibodies and vaccines. Furthermore, Reic underscored the significance of AstraZeneca’s preventative therapeutics in reducing the burden of respiratory infections, citing new real-world data demonstrating Beyfortus’ effectiveness in preventing infant hospitalizations due to RSV.
Key presentations from AstraZeneca during ECCMID include:
Abstract Title Presentation Details
- Beyfortus (nirsevimab) Universal prophylaxis with nirsevimab for prevention of infant hospitalizations due to respiratory syncytial virus. A longitudinal study in Galicia Spain
- Late-breaking oral session Date: April 29, 2024 Time: 11:00 – 12:00 CET
- Sipavibart (AZD3152) Pharmacokinetics and safety of the SARS-CoV-2 monoclonal antibody AZD3152 are consistent with those of tixagevimab/cilgavimab
- Late-breaking poster session Date: April 30, 2024 Time: 12:00 – 13:30 CET
- Sentinel cohort safety of AZD5156/AZD3152 from the phase 1/3 SUPERNOVA trial for COVID-19 prevention in participants with immune impairment
- Poster session Date: April 27, 2024 Time: 12:00 – 13:30 CET
- COVID-19 Real-world evidence
- Individuals with multiple sclerosis are at high risk for COVID-19 hospitalization and death despite high rates of vaccination: results from the England INFORM study
- Oral session Date: April 27, 2024 Time: 08:30 – 10:30 CET
- Continued increased risk of COVID-19 hospitalization and death in immunocompromised individuals despite receipt of ≥4 vaccine doses: updated 2023 results from INFORM, a retrospective health database observational study in England
- Poster session Date: April 27, 2024 Time: 12:00 – 13:30 CET
- High prevalence of immunocompromising conditions among patients with severe acute respiratory infection, including SARS-CoV-2: results from a multicentre, test-negative case-control study
- Poster session Date: April 27, 2024 Time: 12:00 – 13:30 CET
- Immunocompromise, cancer and other comorbidities in patients with severe acute respiratory infection testing positive versus negative for SARS-CoV-2: a post hoc analysis of COVIDRIVE data from May 2021 to May 2023
- Poster session Date: April 27, 2024 Time: 12:00 – 13:30 CET
- COVIDRIVE: a European public-private partnership for generating real-world evidence on the effectiveness of COVID-19 vaccines
- Poster session Date: April 27, 2024 Time: 12:00 – 13:30 CET
- Individuals with multiple sclerosis are at high risk for COVID-19 hospitalization and death despite high rates of vaccination: results from the England INFORM study
- Early Science
- An mRNA vaccine expressing a self-assembling virus-like particle antigen provides a more potent, durable and broader immune response to SARS-CoV-2 in animal models vs native mRNA vaccines
- Late-breaking oral session Date: April 27, 2024 Time: 14:45 – 15:45 CET
- Anti-toxin B neutralizing mAb AZD5148 provides protection in a Clostridioides difficile gnotobiotic piglet model
- Poster session Date: April 30, 2024 Time: 12:00 – 13:30 CET
- An mRNA vaccine expressing a self-assembling virus-like particle antigen provides a more potent, durable and broader immune response to SARS-CoV-2 in animal models vs native mRNA vaccines
AstraZeneca continues to lead the charge in advancing the science of infectious disease protection, with a commitment to developing innovative solutions that address the evolving healthcare landscape.
